Literature DB >> 23839967

High-throughput assessment of Mammalian cell viability by determination of adenosine triphosphate levels.

Nicola Tolliday1.   

Abstract

There are many assays available for high-throughput assessment of mammalian cell viability or cytotoxicity. Approaches include measurement of metabolic capacity, intracellular adenosine triphosphate (ATP) levels, induction of apoptosis, intracellular esterase and protease activity, and cellular membrane integrity. This unit provides an in-depth protocol for measurement of cellular ATP levels as a readout of mammalian cell viability, using the CellTiter-Glo assay from Promega Corporation. A comparison of the key parameters (sensitivity, speed, and cost) for this and other common high-throughput viability assays is also presented. Curr. Protoc. Chem. Biol. 2:153-161
© 2010 by John Wiley & Sons, Inc.

Entities:  

Keywords:  CellTiter‐Glo; cell viability assay; cytotoxicity assay; high‐throughput screening

Year:  2010        PMID: 23839967     DOI: 10.1002/9780470559277.ch100045

Source DB:  PubMed          Journal:  Curr Protoc Chem Biol        ISSN: 2160-4762


  10 in total

1.  Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.

Authors:  Mario Niepel; Marc Hafner; Mirra Chung; Peter K Sorger
Journal:  Curr Protoc Chem Biol       Date:  2017-06-19

2.  Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.

Authors:  Shanthi Kanthala; Sashikanth Banappagari; Ameya Gokhale; Yong-Yu Liu; Gu Xin; Yunfeng Zhao; Seetharama Jois
Journal:  Chem Biol Drug Des       Date:  2014-11-06       Impact factor: 2.817

3.  Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.

Authors:  Sandeep Pallerla; Ted Gauthier; Rushikesh Sable; Seetharama D Jois
Journal:  Eur J Med Chem       Date:  2016-10-10       Impact factor: 6.514

4.  A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer.

Authors:  Jafrin Jobayer Sonju; Achyut Dahal; Sitanshu S Singh; Xin Gu; William D Johnson; Chandra Mohan Reddy Muthumula; Sharon A Meyer; Seetharama D Jois
Journal:  Int J Pharm       Date:  2021-12-09       Impact factor: 6.510

5.  Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides.

Authors:  Tyrslai M Williams; Rushikesh Sable; Sitanshu Singh; Maria Graca H Vicente; Seetharama D Jois
Journal:  Chem Biol Drug Des       Date:  2017-11-16       Impact factor: 2.817

6.  Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.

Authors:  Shanthi Kanthala; Ted Gauthier; Seetharama Satyanarayanajois
Journal:  Biopolymers       Date:  2014-06       Impact factor: 2.505

7.  A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.

Authors:  Sitanshu S Singh; George Mattheolabakis; Xin Gu; Sita Withers; Achyut Dahal; Seetharama Jois
Journal:  Eur J Med Chem       Date:  2021-02-23       Impact factor: 6.514

8.  A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.

Authors:  Shanthi P Kanthala; Yong-Yu Liu; Sitanshu Singh; Rushikesh Sable; Sandeep Pallerla; Seetharama D Jois
Journal:  Oncotarget       Date:  2017-07-05

9.  A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.

Authors:  Mario Niepel; Marc Hafner; Caitlin E Mills; Kartik Subramanian; Elizabeth H Williams; Mirra Chung; Benjamin Gaudio; Anne Marie Barrette; Alan D Stern; Bin Hu; James E Korkola; Joe W Gray; Marc R Birtwistle; Laura M Heiser; Peter K Sorger
Journal:  Cell Syst       Date:  2019-07-10       Impact factor: 10.304

10.  Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy.

Authors:  Himgauri Naik; Jafrin Jobayer Sonju; Sitanshu Singh; Ioulia Chatzistamou; Leeza Shrestha; Ted Gauthier; Seetharama Jois
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.